Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy
Objective To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC‐P) in radical prostatectomy (RP) specimens and predictive value of IDC‐P for biochemical recurrence and adjuvant therapy decision. Method We retrospectively evaluated patients who were performed RP bet...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2021-06, Vol.75 (6), p.e14099-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e14099 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 75 |
| creator | Karakoc, Sedat Celik, Serdar Kaya, Nilhan Bozkurt, Ozan Ellidokuz, Hulya Tuna, Burcin Yorukoglu, Kutsal Mungan, Mehmet Ugur |
| description | Objective
To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC‐P) in radical prostatectomy (RP) specimens and predictive value of IDC‐P for biochemical recurrence and adjuvant therapy decision.
Method
We retrospectively evaluated patients who were performed RP between 2000 and 2014. Among, 67 patients who had stage pT3a tumour with negative surgical margin (Group 1, n = 35) and who had stage pT2 tumour with positive surgical margin (Group 2, n = 32) were included in the study. RP specimens were re‐evaluated for the presence of IDC‐P component and other prognostic factors. In both the groups, prognostic factors were compared according to the presence of IDC‐P and biochemical recurrence status.
Results
In Group 1, IDC‐P was detected in five cases and biochemical recurrence was detected in three cases. Patients with IDC‐P showed significantly higher biochemical recurrence than those without IDC‐P (P = .002). In univariate analysis, IDC‐P was found to be significantly associated with worse progression‐free survival (P |
| doi_str_mv | 10.1111/ijcp.14099 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2492661793</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2492661793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-3fb0c4d151d3184a1f20fc9b01b88978685c83683afd9bc889d5754210dfcc4b3</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhi1UBMvCpT-gitQLQgp47CRrH6sVn0KCQ3u2HH-0jpJ4azug_Hu8LHDggC-2Zp55xzMvQt8Bn0M-F65Tm3OoMOd7aAGripRAKviW37RhZY0pHKKjGDuMSV0zfIAOKW2AM0IWqHsM_u_oY3KqeJL9ZApvCzemIPWkkuwLJYNyox9kYX0opO6mJzmmIuedT_9MkJs5M6N2WiYTC2mTCa9ZlYs3ISvnuEp-mI_RvpV9NCdv9xL9ubr8vb4p7x-ub9e_7ktFOeUltS1WlYYaNAVWSbAEW8VbDC1jfMUaViuWB6PSat6qHNP1qq4IYG2Vqlq6RKc73dz9_2RiEoOLyvS9HI2foiAVJ00DK04z-vMT2vkpjPl3gtSEYUZJs6XOdpTK48RgrNgEN8gwC8Bi64DYOiBeHcjwjzfJqR2M_kDfV54B2AHPrjfzF1Li9m79uBN9AX-tkhs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528083263</pqid></control><display><type>article</type><title>Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Karakoc, Sedat ; Celik, Serdar ; Kaya, Nilhan ; Bozkurt, Ozan ; Ellidokuz, Hulya ; Tuna, Burcin ; Yorukoglu, Kutsal ; Mungan, Mehmet Ugur</creator><creatorcontrib>Karakoc, Sedat ; Celik, Serdar ; Kaya, Nilhan ; Bozkurt, Ozan ; Ellidokuz, Hulya ; Tuna, Burcin ; Yorukoglu, Kutsal ; Mungan, Mehmet Ugur</creatorcontrib><description>Objective
To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC‐P) in radical prostatectomy (RP) specimens and predictive value of IDC‐P for biochemical recurrence and adjuvant therapy decision.
Method
We retrospectively evaluated patients who were performed RP between 2000 and 2014. Among, 67 patients who had stage pT3a tumour with negative surgical margin (Group 1, n = 35) and who had stage pT2 tumour with positive surgical margin (Group 2, n = 32) were included in the study. RP specimens were re‐evaluated for the presence of IDC‐P component and other prognostic factors. In both the groups, prognostic factors were compared according to the presence of IDC‐P and biochemical recurrence status.
Results
In Group 1, IDC‐P was detected in five cases and biochemical recurrence was detected in three cases. Patients with IDC‐P showed significantly higher biochemical recurrence than those without IDC‐P (P = .002). In univariate analysis, IDC‐P was found to be significantly associated with worse progression‐free survival (P < .001). In Group 2, IDC‐P was detected in four cases and biochemical recurrence was detected in 10 cases. Also, tumour volume was significantly higher in patients with IDC‐P than those without IDC‐P (P = .02). IDC‐P was also significantly associated with worse progression‐free survival in Group 2 (P = .033).
Conclusions
In both the groups, IDC‐P was a prognostic factor for progression‐free survival and/or biochemical recurrence. Especially in these patients, the presence of IDC‐P might be helpful for postoperative adjuvant therapy management decision.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.14099</identifier><identifier>PMID: 33619822</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Adjuvants ; Cancer surgery ; Medical prognosis ; Prostate ; Prostate cancer ; Prostatectomy ; Radiation therapy ; Survival ; Tumors ; Urological surgery</subject><ispartof>International journal of clinical practice (Esher), 2021-06, Vol.75 (6), p.e14099-n/a</ispartof><rights>2021 John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-3fb0c4d151d3184a1f20fc9b01b88978685c83683afd9bc889d5754210dfcc4b3</citedby><cites>FETCH-LOGICAL-c3939-3fb0c4d151d3184a1f20fc9b01b88978685c83683afd9bc889d5754210dfcc4b3</cites><orcidid>0000-0002-4725-488X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.14099$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.14099$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33619822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karakoc, Sedat</creatorcontrib><creatorcontrib>Celik, Serdar</creatorcontrib><creatorcontrib>Kaya, Nilhan</creatorcontrib><creatorcontrib>Bozkurt, Ozan</creatorcontrib><creatorcontrib>Ellidokuz, Hulya</creatorcontrib><creatorcontrib>Tuna, Burcin</creatorcontrib><creatorcontrib>Yorukoglu, Kutsal</creatorcontrib><creatorcontrib>Mungan, Mehmet Ugur</creatorcontrib><title>Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Objective
To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC‐P) in radical prostatectomy (RP) specimens and predictive value of IDC‐P for biochemical recurrence and adjuvant therapy decision.
Method
We retrospectively evaluated patients who were performed RP between 2000 and 2014. Among, 67 patients who had stage pT3a tumour with negative surgical margin (Group 1, n = 35) and who had stage pT2 tumour with positive surgical margin (Group 2, n = 32) were included in the study. RP specimens were re‐evaluated for the presence of IDC‐P component and other prognostic factors. In both the groups, prognostic factors were compared according to the presence of IDC‐P and biochemical recurrence status.
Results
In Group 1, IDC‐P was detected in five cases and biochemical recurrence was detected in three cases. Patients with IDC‐P showed significantly higher biochemical recurrence than those without IDC‐P (P = .002). In univariate analysis, IDC‐P was found to be significantly associated with worse progression‐free survival (P < .001). In Group 2, IDC‐P was detected in four cases and biochemical recurrence was detected in 10 cases. Also, tumour volume was significantly higher in patients with IDC‐P than those without IDC‐P (P = .02). IDC‐P was also significantly associated with worse progression‐free survival in Group 2 (P = .033).
Conclusions
In both the groups, IDC‐P was a prognostic factor for progression‐free survival and/or biochemical recurrence. Especially in these patients, the presence of IDC‐P might be helpful for postoperative adjuvant therapy management decision.</description><subject>Adjuvants</subject><subject>Cancer surgery</subject><subject>Medical prognosis</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Radiation therapy</subject><subject>Survival</subject><subject>Tumors</subject><subject>Urological surgery</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU1P3DAQhi1UBMvCpT-gitQLQgp47CRrH6sVn0KCQ3u2HH-0jpJ4azug_Hu8LHDggC-2Zp55xzMvQt8Bn0M-F65Tm3OoMOd7aAGripRAKviW37RhZY0pHKKjGDuMSV0zfIAOKW2AM0IWqHsM_u_oY3KqeJL9ZApvCzemIPWkkuwLJYNyox9kYX0opO6mJzmmIuedT_9MkJs5M6N2WiYTC2mTCa9ZlYs3ISvnuEp-mI_RvpV9NCdv9xL9ubr8vb4p7x-ub9e_7ktFOeUltS1WlYYaNAVWSbAEW8VbDC1jfMUaViuWB6PSat6qHNP1qq4IYG2Vqlq6RKc73dz9_2RiEoOLyvS9HI2foiAVJ00DK04z-vMT2vkpjPl3gtSEYUZJs6XOdpTK48RgrNgEN8gwC8Bi64DYOiBeHcjwjzfJqR2M_kDfV54B2AHPrjfzF1Li9m79uBN9AX-tkhs</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Karakoc, Sedat</creator><creator>Celik, Serdar</creator><creator>Kaya, Nilhan</creator><creator>Bozkurt, Ozan</creator><creator>Ellidokuz, Hulya</creator><creator>Tuna, Burcin</creator><creator>Yorukoglu, Kutsal</creator><creator>Mungan, Mehmet Ugur</creator><general>Hindawi Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4725-488X</orcidid></search><sort><creationdate>202106</creationdate><title>Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy</title><author>Karakoc, Sedat ; Celik, Serdar ; Kaya, Nilhan ; Bozkurt, Ozan ; Ellidokuz, Hulya ; Tuna, Burcin ; Yorukoglu, Kutsal ; Mungan, Mehmet Ugur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-3fb0c4d151d3184a1f20fc9b01b88978685c83683afd9bc889d5754210dfcc4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvants</topic><topic>Cancer surgery</topic><topic>Medical prognosis</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Radiation therapy</topic><topic>Survival</topic><topic>Tumors</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karakoc, Sedat</creatorcontrib><creatorcontrib>Celik, Serdar</creatorcontrib><creatorcontrib>Kaya, Nilhan</creatorcontrib><creatorcontrib>Bozkurt, Ozan</creatorcontrib><creatorcontrib>Ellidokuz, Hulya</creatorcontrib><creatorcontrib>Tuna, Burcin</creatorcontrib><creatorcontrib>Yorukoglu, Kutsal</creatorcontrib><creatorcontrib>Mungan, Mehmet Ugur</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karakoc, Sedat</au><au>Celik, Serdar</au><au>Kaya, Nilhan</au><au>Bozkurt, Ozan</au><au>Ellidokuz, Hulya</au><au>Tuna, Burcin</au><au>Yorukoglu, Kutsal</au><au>Mungan, Mehmet Ugur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-06</date><risdate>2021</risdate><volume>75</volume><issue>6</issue><spage>e14099</spage><epage>n/a</epage><pages>e14099-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Objective
To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC‐P) in radical prostatectomy (RP) specimens and predictive value of IDC‐P for biochemical recurrence and adjuvant therapy decision.
Method
We retrospectively evaluated patients who were performed RP between 2000 and 2014. Among, 67 patients who had stage pT3a tumour with negative surgical margin (Group 1, n = 35) and who had stage pT2 tumour with positive surgical margin (Group 2, n = 32) were included in the study. RP specimens were re‐evaluated for the presence of IDC‐P component and other prognostic factors. In both the groups, prognostic factors were compared according to the presence of IDC‐P and biochemical recurrence status.
Results
In Group 1, IDC‐P was detected in five cases and biochemical recurrence was detected in three cases. Patients with IDC‐P showed significantly higher biochemical recurrence than those without IDC‐P (P = .002). In univariate analysis, IDC‐P was found to be significantly associated with worse progression‐free survival (P < .001). In Group 2, IDC‐P was detected in four cases and biochemical recurrence was detected in 10 cases. Also, tumour volume was significantly higher in patients with IDC‐P than those without IDC‐P (P = .02). IDC‐P was also significantly associated with worse progression‐free survival in Group 2 (P = .033).
Conclusions
In both the groups, IDC‐P was a prognostic factor for progression‐free survival and/or biochemical recurrence. Especially in these patients, the presence of IDC‐P might be helpful for postoperative adjuvant therapy management decision.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>33619822</pmid><doi>10.1111/ijcp.14099</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4725-488X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2021-06, Vol.75 (6), p.e14099-n/a |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2492661793 |
| source | Wiley Online Library - AutoHoldings Journals |
| subjects | Adjuvants Cancer surgery Medical prognosis Prostate Prostate cancer Prostatectomy Radiation therapy Survival Tumors Urological surgery |
| title | Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T21%3A09%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20intraductal%20carcinoma%20for%20adjuvant%20radiotherapy%20candidates%20after%20radical%20prostatectomy&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Karakoc,%20Sedat&rft.date=2021-06&rft.volume=75&rft.issue=6&rft.spage=e14099&rft.epage=n/a&rft.pages=e14099-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.14099&rft_dat=%3Cproquest_cross%3E2492661793%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528083263&rft_id=info:pmid/33619822&rfr_iscdi=true |